Novo Nordisk’s weight loss pill is expanding the obesity treatment market as an alternative to injectable GLP-1 medications. CNBC spoke with patients about their experience on the pill and explains how the drug is facing competition from Eli Lilly’s oral weight loss pill. Watch the video to learn more.
Produced, Shot, and Edited by: Ryan Baker
Reporter: Annika Kim Constantino
Animation by: Emily Park
Managing Producer: Beatriz Bajuelos
Senior Managing Producer: Tala Hadavi
Additional Footage: Novo Nordisk, Eli Lilly, Getty Images
About CNBC: From ‘Wall Street’ to ‘Main Street’ to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Want to get ahead at work with AI? Sign up for CNBC’s new online course, Beyond the Basics: How to Use AI to Supercharge Your Work. Learn advanced AI skills like building custom GPTs and using AI agents to boost your productivity today. Sign up today: https://cnb.cx/4qKBe6H
Connect with CNBC News Online
Get the latest news: https://www.cnbc.com/
Follow CNBC on LinkedIn: https://cnb.cx/LinkedInCNBC
Follow CNBC News on Instagram: https://cnb.cx/InstagramCNBC
Follow CNBC News on Facebook: https://cnb.cx/LikeCNBC
Follow CNBC on Threads: https://cnb.cx/threads
Follow CNBC News on X: https://cnb.cx/FollowCNBC
Follow CNBC on WhatsApp: https://cnb.cx/WhatsAppCNBC
#CNBC
Why Novo Nordisk’s Weight Loss Pill Has Taken Off
source
